Elsevier

Vaccine

Volume 15, Issue 15, October 1997, Pages 1606-1612
Vaccine

Paper
A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal

https://doi.org/10.1016/S0264-410X(97)00100-XGet rights and content

Abstract

A randomized, double-blind trial comparing a diphtheria-tetanus-acellular pertussis vaccine (DTaP) (pertussis toxoid and filamentous hemagglutinin) with a whole-cell vaccine (DTwP) was conducted. A case-contact study was nested in the trial to estimate absolute efficacy. From 1990 through 1994, 4181 children were randomized to receive one of the vaccines at 2, 4, and 6 months. Severe adverse events were monitored weekly during two visits after vaccination. Fewer serious adverse events were observed after DTaP. Surveillance for cough illnesses persisting more than 7 days, in children under 15 years of age, was made by weekly home visits. Examining physicians, blind to vaccination status, took samples for culture and serologic testing. Pertussis was defined as 21 or more days of cough confirmed by culture, serology, or contact with a culture-confirmed person. Beginning 28 days after the third vaccine dose, the overall ratio of pertussis incidence in the DTaP group relative to the DTwP group (RRacwc) was 1.54 (95% CI, 1.23–1.93). In children younger than 18 months of age, RRacwc was 1.16 (95% CI, 0.77–1.73) and 1.76 (95% CI, 1.33–2.33) in children older than 18 months, which suggests a shorter duration of protection with the acellular vaccine (P = 0.090). Absolute efficacy estimates derived from the case-contact study confirmed the lower protection afforded by the acellular vaccine compared with the whole-cell vaccine: 31% (95% CI, 7–49) versus 55% against the protocol case definition, and 85% (95% CI, 66–93) versus 96% for the more severe WHO case definition. Although vaccination with DTaP provided a lower degree of protection than the highly effective DTwP, this difference was less prominent before 18 months of age, the customary age for a fourth dose. The safer DTaP vaccine may prove a valuable substitute for whole-cell vaccines when used in a schedule that includes a booster dose.

References (28)

  • F. Simondon et al.

    Comparative study of the safety and immunogenicity of a DT-acellular pertussis and a DT-Whole-cell pertussis vaccine in Senegalese infants

    European Journal of Clinical Microbiology and Infectious Diseases

    (1996)
  • P.E.M. Fine et al.

    Reflections on the efficacy of pertussis vaccines

    Review of Infectious Diseases

    (1987)
  • Placebo controlled trial of two acellular vaccines in Sweden—protective efficacy and adverse events

    Lancet

    (1988)

    Placebo controlled trial of two acellular vaccines in Sweden—protective efficacy and adverse events

    Lancet

    (1988)
  • J. Storsaeter et al.

    Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance

    Vaccine

    (1992)
  • K.M. Edwards et al.

    Comparison of 13 acellular pertussis vaccines: overview and serologic responses

    Pediatrics

    (1995)
  • Preziosi, M.P., Wassilak, S.,Yam, A., Ndiaye, M., Simaga, A. and Simondon, F. Practical experiences in obtaining...
  • J. Regan et al.

    Enrichment medium for the isolation of Bordetella

    Journal of Clinical Microbiology

    (1977)
  • C.R. Manclark et al.

    Serological response to Bordetella pertussis

  • E. Grimprel et al.

    Comparison of polymerase chain reaction, culture, and western immunoblot serology for diagnosis of Bordetella pertussis infection

    Journal of Clinical Microbiology

    (1993)
  • E. Reizenstein

    Diagnostic polymerase chain reaction

  • N.E. Breslow et al.

    Statistical methods in cancer research: Vol 2. The design and analysis of cohort studies

  • K.J. Rothman

    Modern Epidemiology

    (1986)
  • SAS version 6.10. Statistical Analysis Systems Institute Inc., Cary, NC,...
  • Cited by (224)

    • Epidemiology, prevention and control of pertussis in Spain: New vaccination strategies for lifelong protection

      2022, Enfermedades Infecciosas y Microbiologia Clinica
      Citation Excerpt :

      Several clinical studies have estimated efficacies of about 84–85% and 71–78% in the prevention of typical and mild pertussis, respectively, for acellular vaccines formulated with at least three bacterial antigens.40,41 Simondon and colleagues estimated the efficacy of a 2-component vaccine at 85%, which led to its approval within the regulatory framework and implementation in vaccination programmes.42 A single-component vaccine (PT) is still in use in northern Europe, with an efficacy of 71%.43

    • Dose-dependent effectiveness of acellular pertussis vaccine in infants: A population-based case-control study

      2020, Vaccine
      Citation Excerpt :

      We calculated effectiveness point estimates of 42.1% after the first dose of aPV, increasing with each dose of the primary series (83.9% after 2, 98.2% after 3, and 100% after 4 doses). These findings are in agreement with previous observational studies which have consistently shown approximately 50% protection against pertussis in infancy following a first dose of either wPV or aPV, and at least 80% protection after 2 doses [3,7,15–20]. As the evidence is consistent with incremental protection after each additional dose, it is essential to complete recommended doses in a timely fashion to achieve optimal protection conferred by pertussis vaccine.

    • Pertussis vaccines and protective immunity

      2019, Current Opinion in Immunology
    View all citing articles on Scopus

    Present address: Unité de Recherche sur les Maladies Infectieuses et Parasitaires, Centre ORSTOM de Montpellier, 34032 Montpellier, France.

    View full text